DORM News Alert Dorman Products (DORM) 47.81 02/14/2015 11:4

New Post Public Reply Private Reply Replies (0) Message Board

Feb 14, 2015 at 12:44 PM

Dorman Products (DORM) 47.81 $DORM

14.3% Return Seen to Date on SmarTrend Dorman Products Call (DORM)
Comtex SmarTrend(R) - Fri Jan 09, 9:28AM CST
SmarTrend identified an Uptrend for Dorman Products (NASDAQ

ORM) on October 3rd, 2014 at $44.07. In approximately 3 months, Dorman Products has returned 14.27% as of today's recent price of $50.36.
DORM: 47.81 (-0.05)

My Top Auto Components Stocks For 2015
Stan Stafford - at Seeking Alpha - Tue Jan 06, 4:16AM CST

SRI: 12.13 (-0.12), CPS: 54.36 (-0.13), CAAS: 6.37 (+0.14), MOD: 12.68 (+0.10), DW: 52.46 (-0.02), REMY: 22.59 (-0.22), DLPH: 78.70 (+0.64), THRM: 41.21 (+0.38), TEN: 58.07 (+0.19), VC: 100.92 (-0.08), MPAA: 24.08 (-0.05), DORM: 47.81 (-0.05), DAN: 22.96 (-0.04), SHLO: 13.17 (+0.05), SUP: 19.36 (+0.02), FOXF: 16.14 (+0.31), TRW: 103.60 (-0.06), CXDC: 3.98 (unch), ALV: 113.36 (-0.26), AXL: 24.73 (-0.22), SPAR: 5.46 (unch), GNTX: 17.81 (+0.27), TOWR: 27.89 (-0.20), FDML: 15.23 (-0.04), LEA: 108.70 (-0.73), BWA: 60.17 (-1.21), FSYS: 10.93 (+0.11), GT: 25.91 (-0.30), SMP: 39.33 (-0.14), STRT: 65.10 (+0.29), CTB: 36.73 (-0.29), MGA: 102.32 (-0.46), JCI: 48.50 (+0.50)

Dorman Products Is A Long-Term Buy
Zain Abidin - at Seeking Alpha - Tue Dec 09, 9:43AM CST

DORM: 47.81 (-0.05)

Dorman Products Shares Up 14.8% Since SmarTrend's Buy Recommendation (DORM)
Comtex SmarTrend(R) - Thu Dec 04, 9:49AM CST
SmarTrend identified an Uptrend for Dorman Products (NASDAQ

ORM) on October 3rd, 2014 at $44.07. In approximately 2 months, Dorman Products has returned 14.82% as of today's recent price of $50.60.
DORM: 47.81 (-0.05)

Earnings Look Back: Dorman Products Is Up 11.3% Since Reporting Quarterly Results 2 Weeks Ago (DORM)
Comtex SmarTrend(R) - Mon Nov 17, 1:31PM CST
When Dorman Products (NASDAQ

ORM) reported earnings two weeks ago on October 28th, 2014, analysts, on average, expected the company to report earnings of $0.69 on sales of $201.8 million. The company actually reported EPS of $0.68 on sales of $197.8 million, missing EPS estimates by $0.01 and missing revenue estimates by $4.0 million. Shares of Dorman Products have climbed from $42.67 to $47.50, representing a gain of 11.3% since the company reported earnings 20 days ago.
DORM: 47.81 (-0.05)

Dorman Products Earnings Review: 13 Days after Announcement Shares Up 9.2% (DORM)
Comtex SmarTrend(R) - Mon Nov 10, 12:21PM CST
A week ago on October 28th, 2014 Dorman Products (NASDAQ

ORM) reported earnings and analysts, on average, expected earnings of $0.69 on sales of $201.8 million. The company actually reported EPS of $0.68 on sales of $197.8 million, missing EPS estimates by $0.01 and missing revenue estimates by $4.0 million. Since the company's report, shares of Dorman Products have risen from $42.67 to $46.60, representing a gain of 9.2% in the past 13 days.
DORM: 47.81 (-0.05)

Dorman Products misses Street 3Q forecasts
Automated Insights - Tue Oct 28, 6:06AM CDT
COLMAR, Pa. (AP) _ Dorman Products Inc. (DORM) on Tuesday reported net income of $24.5 million in its third quarter.
DORM: 47.81 (-0.05)

Dorman Products misses by $0.01, misses on revenue
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 6:06AM CDT

DORM: 47.81 (-0.05)

Dorman Products, Inc. Reports Sales and Earnings for the Third Quarter Ended September 27, 2014; Announces Expansion and Extension of Stock Repurchase Program
Marketwired - Tue Oct 28, 6:01AM CDT
Dorman Products, Inc. (NASDAQ: DORM)
DORM: 47.81 (-0.05)

Dorman Products Shares Down 27.3% Since SmarTrend's Sell Call (DORM)
Comtex SmarTrend(R) - Wed Oct 01, 9:41AM CDT
SmarTrend identified a Downtrend for Dorman Products (NASDAQ

ORM) on May 8th, 2014 at $55.05. In approximately 5 months, Dorman Products has returned 27.34% as of today's recent price of $39.99.
DORM: 47.81 (-0.05)

Dorman Products Has Returned 25.0% Since SmarTrend Recommendation (DORM)
Comtex SmarTrend(R) - Wed Sep 24, 9:12AM CDT
SmarTrend identified a Downtrend for Dorman Products (NASDAQ

ORM) on May 8th, 2014 at $55.05. In approximately 5 months, Dorman Products has returned 24.97% as of today's recent price of $41.30.
DORM: 47.81 (-0.05)

Dorman Products Down 18.1% Since SmarTrend Downtrend Call (DORM)
Comtex SmarTrend(R) - Tue Sep 02, 10:00AM CDT
SmarTrend identified a Downtrend for Dorman Products (NASDAQ

ORM) on May 8th, 2014 at $55.04. In approximately 4 months, Dorman Products has returned 18.14% as of today's recent price of $45.06.
DORM: 47.81 (-0.05)

Downtrend Call Working As Dorman Products Stock Falls 21.0% (DORM)
Comtex SmarTrend(R) - Mon Aug 18, 11:12AM CDT
SmarTrend identified a Downtrend for Dorman Products (NASDAQ

ORM) on May 8th, 2014 at $55.05. In approximately 3 months, Dorman Products has returned 21.01% as of today's recent price of $43.48.
DORM: 47.81 (-0.05)

Post Earnings Update: Dorman Products Has Sunk 1.9% Lower in Past 2 Weeks (DORM)
Comtex SmarTrend(R) - Mon Aug 18, 9:29AM CDT
19 days ago, on July 30th, 2014, Dorman Products (NASDAQ

ORM) reported its earnings. Analysts, on average, expected earnings of $0.65 per share on sales of $186.8 million. The company actually reported EPS of $0.64 on sales of $196.2 million, missing EPS estimates by $0.01 and beating revenue estimates by $9.4 million. Since the company's report, shares of Dorman Products have fallen from $44.01 to $43.17, representing a loss of 1.9% in the past 19 days.
DORM: 47.81 (-0.05)

Earnings Look Back: Dorman Products Is Down 4.0% Since Reporting Quarterly Results 1 Week Ago (DORM)
Comtex SmarTrend(R) - Mon Aug 11, 11:59AM CDT
12 days ago, on July 30th, 2014, Dorman Products (NASDAQ

ORM) reported its earnings. Analysts, on average, expected earnings of $0.65 per share on sales of $186.8 million. Dorman Products actually reported earnings of $0.64 per share on sales of $196.2 million, missing EPS estimates by $0.01 and beating revenue estimates by $9.4 million. Shares of Dorman Products have slipped from $44.01 to $42.23, representing a loss of 4.0%, since the company reported earnings 12 days ago.
DORM: 47.81 (-0.05)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

JiMMYBAR! Unveils World's First Creatine Trail Mix

The New Face of Snacking: Creatine Trail Mix I'll tell you right off the bat, JiMMYBAR! seems to be cornering the snack world with an odd—but interesting—twist. They've just launched the world's first Creatine + Protein Trail Mix, blending muscle-building nutrients with the classic crunch of trail mix. Sounds quirky, and it’s exclusive to their site, JiMMYBARs.com....

Jaguar Promise Tackles College Cost for Texas Students

Transforming Aspirations into Achievements In the heart of San Antonio, something’s cooking at A&M University-San Antonio, and it's not just the classic breakfast tacos. They've hit a record-breaking enrollment of 7,697 students this Fall, with 1,322 being fresh-faced first-timers. And while that might grab your attention, the real headliner is their Jaguar Promise...

xFusion Tackles Cooling and Power at OCP 2026

Bracing for an AI Revolution Ah, the world of AI — it's like the wild west out there, with data centers struggling to keep up as workloads skyrocket. Enter xFusion, a veteran in the computing infrastructure game, rolling out some seriously impressive tech at the 2026 Open Compute Project (OCP) Global Summit. The company's latest offering showcases how they're tackling...

Puori Protein Transparency Pays Off Amid Lead Scare

Puori's Moment of Reckoning The world of nutritional supplements is no stranger to controversy, but when Puori found itself caught in the storm of the Consumer Reports investigation last year, it chose a road less traveled: transparency and accountability. Faced with alarming news that over two-thirds of tested protein powders exceeded California's Proposition 65 lead...

New Data on SKYRIZI Offers Hope for Crohn's Patients

Treating Crohn's: New Hope on the Horizon Folks, let me tell you, the landscape for treating Crohn's disease just got a bit more interesting. AbbVie's Phase 3 AFFIRM study has brought some attention-grabbing data on the table, showcasing the potential of their drug, SKYRIZI® (risankizumab-rzaa). This ain't just another run-of-the-mill study; these results could be a...

Honeywell Aerospace Faces Legal Turbulence in Fraud Case

If you've got your chips on Honeywell Aerospace, Inc. (HONA), buckle up because things are getting choppy. Investors who took a bath on their shares now have the chance to put on their legal gloves and join a securities fraud class action lawsuit against the company. Legal Storm Over Misleading Statements Here's the rub: Between June 29 and September 1, 2026, the folks at...

AI-Powered Travel Transformation in Norway Revealed

AI-Driven Travel Meets Norway's Authentic Charm Well, folks, once again we're staring down the barrel of technology going full throttle in the travel game. Mindtrip, the savvy AI-powered travel platform, just inked a deal with the Norwegian Travel Cluster. It's their first tango in Europe, and they're not dipping their toes—they're diving headfirst into the icy fjords....

Tessa AI: Revolutionizing Biomedical Research with AI

Shaking Up Research Evaluation When Siensmetrica decided it was high time for a name change, morphing into Tessa AI wasn't just a cosmetic shift. It was a nod to what stakeholders were already calling it and laid the ground for a broader mission statement. They're not sitting on their hands; they're crafting tools that tackle the scientific life cycle from start to...

Laars Welcomes Women in Manufacturing to Facility Tour

Opening Doors and Minds in Manufacturing On October 15, Laars Heating Systems throws wide open its Rochester, N.H., facility to a group that's rewriting the rulebook: women in manufacturing. It's not just another day in the life of assembly lines and engineering desks, folks. This is about giving a platform to those often sidelined in the field of boilers and water...

WIN Expands Leadership Amidst Rapid Growth Surge

Why WIN's Leadership Shake-Up Matters Change is afoot at the fertility and family support powerhouse WIN, and there's no mistaking the bold handwriting on the wall. As they swell towards supporting one million families, WIN's revamping their leadership table with three key players aimed at pushing the envelope further than before. They've got Claudio Stefan, Stacey...